|Bid||68.68 x 1200|
|Ask||70.00 x 800|
|Day's range||66.00 - 69.95|
|52-week range||27.77 - 116.91|
|Beta (5Y monthly)||1.76|
|PE ratio (TTM)||N/A|
|Earnings date||07 Nov 2022 - 11 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||92.27|
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 5.56% and 26.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders will doubtless be very grateful to see the share price up 78% in...
Beam Therapeutics (NASDAQ: BEAM), a pre-clinical gene-editing company, saw its shares dip by as much as 9.8% in early morning trading Monday. Ahead of the opening bell, Beam announced that the Food and Drug Administration (FDA) placed a clinical hold on its relapsed/refractory T-cell acute lymphoblastic leukemia candidate known as BEAM-201. Beam didn't provide a reason for the clinical hold in its early morning press release.